Company Profile
Becton Dickinson Stock Price, News & Analysis
Company overview
Business overview
Becton Dickinson is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NYSE, Becton Dickinson is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Becton Dickinson follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Becton Dickinson sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Why the stock is moving
BDX is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Becton Dickinson’s catalysts are hospital-product demand, platform execution, and any margin or portfolio update that clarifies the company’s operating path. The market will care about steady execution more than a binary event.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
BD Reports Second Quarter Fiscal 2026 Financial Results
Source: Becton Dickinson
- 02
BD Appoints Vitor Roque Chief Financial Officer
Source: Becton Dickinson
- 03
- 04
- 05
Rick Byrd to Retire from BD
Source: Becton Dickinson
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.